Definium Therapeutics Inc. (NASDAQ:DFTX) experienced a significant surge in pre-market trading on Monday following the announcement of positive results from its Phase 3 clinical trial for DT120, an LSD-based orally disintegrating tablet designed to treat major depressive disorder. The stock was quoted at $40.19 on Public.com at 9:00 a.m. ET, marking a 64.2% increase from Friday's closing price of $24.48.
The company reported that the Emerge trial successfully met its primary endpoint, demonstrating an 8.1-point placebo-adjusted reduction on the Montgomery-Åsberg Depression Rating Scale (MADRS) at week six. This result surpassed analyst expectations, with Jefferies analysts previously indicating that a 4- to 5-point difference would be considered a strong showing. The actual outcome was 62% above the top end of that range.
Additional data from the trial revealed a 14.2-point benefit versus placebo at week one and a 7.3-point gap at week 12, suggesting a rapid and sustained effect. The response rate for DT120 was 35% compared to 7% for placebo, yielding a number needed to treat (NNT) of approximately four. Remission rates stood at 24% for the drug versus 3% for placebo, with an NNT of about five. The company reported no serious adverse events and no signs of suicidality.
CEO Rob Barrow characterized the results as "rapid, robust, and durable," while investigator John Sonnenberg described the benefit as "meaningful and durable." Definium, which changed its name from MindMed earlier this year, is now preparing for the next steps in the regulatory process, which include a second Phase 3 depression trial and potential scheduling reviews by the DEA and state authorities.
The positive readout also influenced peers in the psychedelic therapeutics space. Compass Pathways (NASDAQ:CMPS), which is developing a psilocybin treatment for depression, saw its shares rise 4.8% in sympathy. However, the broader market context highlights the challenges ahead for Definium, including controlled-substance scheduling, commercial site limitations, and market access uncertainties.
From a financial perspective, Definium reported $373.4 million in cash, cash equivalents, and investments as of March 31, which the company expects to fund operations into 2028. Research and development spending increased to $41.5 million in the first quarter, up from $23.4 million a year ago. The company has yet to generate revenue and continues to post losses, typical for clinical-stage biotechs.
Monday's pre-market movement positions DFTX above its previous 52-week high, but traders should be aware of the gap risk. If the stock maintains its gains through the open, focus may shift to the approval and commercialization risks that lie ahead, including the outcome of the second depression trial and the regulatory pathway for a Schedule I substance.
